AMLX Q4 2025 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0+100.0% YoY

Gross Profit

$20M

Operating Income

-$37M

Net Income

-$33M

EPS (Diluted)

$-0.28

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$333M

Total Liabilities

$27M

Stockholders' Equity

$305M

Cash & Equivalents

$227M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	-$665,000	+100.0%
Gross Profit	$20M	-$665,000	+3106.9%
Operating Income	-$37M	-$41M	+10.0%
Net Income	-$33M	-$38M	+12.1%